KLEIN JOSEPH III 4

4 · IONIS PHARMACEUTICALS INC · Filed May 5, 2026

AI-generated summary of this filing

Updated May 5, 2026

Ionis (IONS) Director Joseph Klein III Exercises Options, Sells Shares

What Happened

Joseph Klein III, a director of Ionis Pharmaceuticals (IONS), exercised 10,111 options on May 1, 2026 at $47.11 per share (total cost $476,329) and sold the resulting 10,111 shares the same day in two open‑market transactions. The sales generated total proceeds of $743,238 (8,680 shares at a weighted avg $73.35 for $636,704; 1,431 shares at a weighted avg $74.45 for $106,534). Net proceeds before taxes and fees were roughly $266,909. The filing also lists a derivative conversion/disposition at $0.00 reflecting the option conversion to underlying shares.

Key Details

Transaction date: 2026-05-01 (filed 2026-05-05 — timely under the two business day rule)
Exercise: 10,111 shares @ $47.11, cost = $476,329
Sales: 8,680 shares @ weighted avg $73.35 (range $72.95–$73.64) = $636,704; 1,431 shares @ weighted avg $74.45 (range $74.07–$74.92) = $106,534; total sales = $743,238
Net proceeds before taxes/fees: approx. $266,909
Shares owned after the reported transactions: not stated in the information provided
Footnotes of note:
- Sales were made under a Rule 10b5‑1 trading plan adopted Nov 25, 2025 (F1)
- Reported sale prices are weighted averages; price ranges provided for the individual blocks (F2, F3)
- Reporting person disclaims beneficial ownership of securities held by his son (F4)

Context

This is effectively a cashless exercise: options were exercised and the resulting shares were sold the same day. Such transactions commonly reflect option exercise and liquidity needs and are not by themselves an indicator of the director’s view on the company’s longer‑term prospects.
The 10b5‑1 plan note indicates the sales were pre‑arranged, which can be used to avoid questions about contemporaneous trading intent.

Form 4

Period: 2026-05-01

Director

Transactions

Exercise/Conversion
Common Stock
2026-05-01$47.11/sh+10,111$476,329→ 21,125 total
Sale
Common Stock
[F1][F2]
2026-05-01$73.35/sh−8,680$636,704→ 12,445 total
Sale
Common Stock
[F1][F3]
2026-05-01$74.45/sh−1,431$106,534→ 11,014 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-05-01−10,111→ 0 total
Exercise: $47.11From: 2025-07-01Exp: 2034-06-30→ Common Stock (10,111 underlying)

Holdings

Footnotes (4)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.95 to $73.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.07 to $74.92 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Joseph Klein, III|2026-05-04

1 file